Search research articles
Contact Us
Filters
Showing results (11-20 of 238) with videos related to
Page
of 24
Sort By:
The New England Journal of Medicine
|
December 30, 2025
Monoclonal Gammopathy of Undetermined Significance
Majdolen Istaiti, Ola Landgren, Ari Zimran
The New England Journal of Medicine
|
February 19, 2005
The glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews
Ari Zimran, Orit Neudorfer, Deborah Elstein
Immunology and Cell Biology
|
June 17, 2009
Glucocerebroside: an evolutionary advantage for patients with Gaucher disease and a new immunomodulatory agent
Yaron Ilan, Deborah Elstein, Ari Zimran
Best Practice & Research. Clinical Endocrinology & Metabolism
|
May 20, 2015
The emergence of Parkinson disease among patients with Gaucher disease
Deborah Elstein, Roy Alcalay, Ari Zimran
Hematology (Amsterdam, Netherlands)
|
December 12, 2003
Platelet counts and interleukin-6 (IL-6) promoter polymorphism in patients with Gaucher disease
Deborah Elstein, Gheona Altarescu, Ari Zimran
Blood Cells, Molecules & Diseases
|
May 3, 2006
Increased incidence of Parkinson disease among relatives of patients with Gaucher disease
Assaf Halperin, Deborah Elstein, Ari Zimran
The Israel Medical Association Journal : IMAJ
|
January 7, 2015
Screening for Gaucher disease: new challenges
Ari Zimran, Gheona Altarescu, Deborah Elstein
Blood Cells, Molecules & Diseases
|
September 23, 2017
Should eliglustat be first line therapy for patients with type 1 Gaucher disease? Definitions of safety and efficacy
Ari Zimran, Jack Goldblatt, Jeff Szer
Blood
|
July 25, 2006
Low-dose therapy trumps high-dose therapy again in the treatment of Gaucher disease
Ari Zimran, Deborah Elstein, Ernest Beutler
American Journal of Hematology
|
February 21, 2009
Enzyme replacement therapy for mild patients with Gaucher disease
Ari Zimran, Yaron Ilan, Deborah Elstein
Page
of 24
Search research articles
Search
Showing results (11-20 of 238) with videos related to
Sort By:
Page
of 24
The New England Journal of Medicine
|
December 30, 2025
Monoclonal Gammopathy of Undetermined Significance
Majdolen Istaiti, Ola Landgren, Ari Zimran
The New England Journal of Medicine
|
February 19, 2005
The glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews
Ari Zimran, Orit Neudorfer, Deborah Elstein
Immunology and Cell Biology
|
June 17, 2009
Glucocerebroside: an evolutionary advantage for patients with Gaucher disease and a new immunomodulatory agent
Yaron Ilan, Deborah Elstein, Ari Zimran
Best Practice & Research. Clinical Endocrinology & Metabolism
|
May 20, 2015
The emergence of Parkinson disease among patients with Gaucher disease
Deborah Elstein, Roy Alcalay, Ari Zimran
Hematology (Amsterdam, Netherlands)
|
December 12, 2003
Platelet counts and interleukin-6 (IL-6) promoter polymorphism in patients with Gaucher disease
Deborah Elstein, Gheona Altarescu, Ari Zimran
Blood Cells, Molecules & Diseases
|
May 3, 2006
Increased incidence of Parkinson disease among relatives of patients with Gaucher disease
Assaf Halperin, Deborah Elstein, Ari Zimran
The Israel Medical Association Journal : IMAJ
|
January 7, 2015
Screening for Gaucher disease: new challenges
Ari Zimran, Gheona Altarescu, Deborah Elstein
Blood Cells, Molecules & Diseases
|
September 23, 2017
Should eliglustat be first line therapy for patients with type 1 Gaucher disease? Definitions of safety and efficacy
Ari Zimran, Jack Goldblatt, Jeff Szer
Blood
|
July 25, 2006
Low-dose therapy trumps high-dose therapy again in the treatment of Gaucher disease
Ari Zimran, Deborah Elstein, Ernest Beutler
American Journal of Hematology
|
February 21, 2009
Enzyme replacement therapy for mild patients with Gaucher disease
Ari Zimran, Yaron Ilan, Deborah Elstein
Page
of 24